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Toso, a Cell Surface, Specific Regulator
of Fas-Induced Apoptosis in T Cells
capable of activating cysteine proteases called cas-
pases (Tewari and Dixit, 1995). Recent studies have im-
plicated caspase-8 (MACH [MORT1-associated CED-3
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homologue]/FLICE [FADD-like ICE]/Mch5) as linking FasShigemi Kinoshita,1 and Garry P. Nolan1,2,10
receptor signaling to downstream caspases via its asso-1Department of Molecular Pharmacology
ciation with the Fas-associated death domain (FADD)/2Department of Microbiology and Immunology
MORT1 (Boldinet al., 1995, 1996; Chinnaiyanet al., 1995;3Department of Genetics
Fernandes-Alnemri et al., 1996; Muzio et al., 1996). Sev-4Howard Hughes Medical Institute
eral groups have reported that caspase-8 activation isStanford University School of Medicine
inhibited by a cellular inhibitor, cFLIP (cellular FLICE-Stanford, California 94305
inhibitory protein)/FLAME-1 (FADD-like anti-apoptotic5 Institute of Medical Science
molecule-1)/I-FLICE (inhibitor of FLICE) (Hu et al., 1997;The University of Tokyo
Irmler et al., 1997; Srinivasula et al., 1997).Tokyo 108
A balance between life and programmed death incellsJapan
is likely to be governed by multiple interacting regulators6Rigel, Inc.
that counteract apoptotic signals with appropriate anti-772 Lucerne Drive
apoptotic signals. Imbalances in this regulation can re-Sunnyvale, California 94086
sult in wide variety of diseases, including cancer and7The Burnham Institute
immune dysfunction, and it is now clear that there areLa Jolla, California 92037
polypeptides other than Fas that contribute to dysregu-
lation of appropriately induced apoptosis. As an exam-
ple, in many tumor cell lines Fas expression does not
Summary correlate with sensitivity to Fas-induced apoptosis, im-
plying the existence of Fas-resistance protein (Richard-
Fas is a surface receptor that can transmit signals for son et al., 1994). Also, in some types of cells, Fas-
apoptosis. Using retroviral cDNA library±based func- induced apoptosis requires protein synthesis inhibitors
tional cloning we identified a gene, toso, that blocks such as cycloheximide, and even in Fas-sensitive cells,
Fas-mediated apoptosis. Toso expression was con- protein synthesis inhibitors can play a synergistic role
fined to lymphoid cells and was enhanced after cell- with cycloheximide (Yonehara et al., 1989; Itoh and Na-
specific activation processes in T cells. Toso appeared gata, 1993). These combined observations further sug-
limited to inhibition of apoptosis mediated by mem- gest the existence of proteins capable of suppressing
bers of the TNF receptor family and was capable of Fas-generated apoptotic signaling.
In addition, in the course of a normal immune re-inhibiting T cell self-killing induced by TCR activation
sponse, both cytotoxic T cell and natural killer cell acti-processes that up-regulate Fas ligand. We mapped
vation can lead to FasL induction (Arase et al., 1995;the effect of Toso to inhibition of caspase-8 process-
Berke, 1995; Montel et al., 1995). Although both Fasing, the most upstream caspase activity in Fas-medi-
and FasL are rapidly induced following T cell activation,ated signaling, potentially through activation of cFLIP.
activated T cells remain resistant to Fas-induced apo-Toso therefore serves as a novel regulator of Fas-
ptosis for several days (Owen-Schaub et al., 1992; Klasmediated apoptosis and may act as a regulator of cell
et al., 1993). Thus, a mechanism exists to shield newlyfate in T cells and other hematopoietic lineages.
activated T cells from the cytotoxicity of their own FasL
expression. This is likely to be an important componentIntroduction
of T cell activation processes and protection in lymph
nodes, splenic germinal centers, and other sitesat whichApoptosis is an important homeostatic mechanism that
T cell activation might result in apoptosis of target cells.maintains cell number, positioning, and differentiation.
Therefore blockers of Fas-induced apoptosis must existSeveral intracellular and intercellular processes are known
in T cells.
to regulate apoptosis. One of the best characterized
We therefore devised a geneticscreen to identify such
systems is initiated by the cell surface receptor Fas
regulators within activated T cells. Here we report the
(Apo-1/CD95), which initiates apoptosis in a wide range identification and molecular cloning of a novel surface
of organisms (Yonehara et al., 1989; Itoh et al., 1991). molecule, Toso, through a retroviral cDNA library±based
Clustering of the Fas cytoplasmic domain generates functional screening system. toso is a member of the
an apoptotic signal via the ªdeath domainº (Itoh and immunoglobulin gene superfamily and specifically inhib-
Nagata, 1993). Fas engagement by Fas ligand (FasL) is its tumor necrosis factor (TNF) receptor family member±
mediated apoptosis. The results demonstrate the exis-
tence of cell surface±mediated mediated signaling
8 Present address: Rigel, Inc., 772 Lucerne Drive, Sunnyvale, Califor- pathways that lead to down-regulation of Fas-mediated
nia 94086.
apoptosis in certain cell types, and suggest that activa-9 Present address: Carilion Roanoke Community Hospital, Virginia
tion of T cells suppresses internal signaling systems24029.




Figure 1. Primary Structure of Toso
(A) Deduced amino acid sequence of the
Toso gene product. Twohydrophobic regions
are underlined: a leader sequence (single
underline) and a presumptive transmembrane
region (double underline).
(B) Kyte-Dolittle hydropathy plot analysis of
the Toso gene product (top) and schematic
presentation of Toso (bottom). The diagram
shows the leader sequence (hatched bar),
the extracellular domain (ED), the trans-
membrane region (TM, shaded bar), the cyto-
plasmic domain (CD), the immunoglobulin
domain (Ig), the basic amino acid±rich region
(Basic), the proline-rich region (Proline), and
the acidic amino acid-rich region (Acidic).
(C) BLAST search resultsusing the Toso gene
product. The position of the first amino acid
in each sequence is given to the left of the
alignment. Dashes indicate gaps; dark and
light shading refer to identical and similar res-
idues, respectively. The aligment shows IgVH
(G1HUNM), IgVl (L1MS4E), T cell receptor
(TCR) Va (RWMSAV), TCR Vb (RWHUVY), CD4
(U47924), CD8 chain II (X04310), Poly Ig R
(QRRBG), immunoglobulin V-set consensus
sequence, acid sphingomyelinase, insulin re-
ceptor substrate-1 (IRS-1), and apoptosis in-
hibitor, IAP, from O. pseudotsugata nuclear
polyhedrosis virus (Op-IAP). Arrowheads in-
dicate positions characteristic of many V-set
sequences.
Results induced apoptosis, of which 12 carried cDNA inserts.
The cDNA inserts were recloned and transduced into
Jurkat cells to verify for their effect using anti-Fas mono-Molecular Cloning and Chromosomal Localization
of a Molecule That Inhibits clonal antibody (mAb). After this second round of anti-
Fas screening, one clone, termed Toso, demonstratedFas-Induced Apoptosis
To screen for cDNAs that encode inhibitory molecules potent inhibition of Fas-induced apoptotic signaling.
The cDNA insert of toso contains a 59 noncoding re-for Fas-induced apoptosis, we infected 7.7 3 106 Jurkat
cells with a retroviral Jurkat T cell cDNA library. Under gion of 73 nucleotides, a coding region of 1173 nucleo-
tides (390 amino acids), and a 39 noncoding region ofthese conditions, Fas activation of lacZ control±infected
cells resulted in a spontaneous background of two or 665 nucleotides. The ATG initiation codon is contained
within a standard Kozak consensus sequence. Kyte-three clones per 106 Jurkat cells. In our library screening
we obtained 26 clones that were resistant to Fas- Doolittle hydropathy plot analysis showed that Toso has
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two hydrophobic regions: the amino-terminal residues
from 1 to 17 correspond to the deduced signal se-
quence, and the residues from 254 to 272 correspond
to a presumptive transmembrane region (Figure 1A,
underlined and double underlined, respectively) (Hof-
mann and Stoffel, 1992), suggesting that Toso is a type
1 integral membrane protein. The predicted molecular
weight of Toso is 41 kDa. The cytoplasmic region of
Toso has a basic amino acid±rich region (K273±R323),
a proline-rich region (P334±P346), and an acidic amino
acid±rich region (E378±D384) (Figures 1A and 1B). Basic
local alignment search technique (BLAST) analysis re-
vealed that toso is a unique gene (Altschul et al., 1990).
The extracellular domain of Toso has homology to
the immunoglobulin variable (IgV) domains, which are
characterized by motifs in the b strand B, D, and F
regions, (residues VTLTC, RV(or F,I) and DSG(or A)-Y-
CA ) (Williams and Barclay, 1988). Importantly, the cyste-
ines in the IgV-like motif VTIKC at position 33 in Toso,
as well as the cysteine in the IgV-like motif DSGVYAC
at position 98, are appropriately distanced as in other
IgV-like domains to form a disulphide bond. Toso also
contains within the immunoglobulin domains two addi-
tional cysteines that are not conserved in other IgV-like
domains. Thus, the presumptive extracellular domains
has all of the requisite features that demarcate it as a
potential IgV-like domain. The cytoplasmic region of
Toso has partial homology to FAST kinase (Fas-acti-
vated serine/threonine kinase), acid sphingomyelinase, Figure 2. Differential Inhibition of Apoptosis by Toso and Relation
insulin receptor substrate-1, and the apoptosis inhibitor to TNFa-Mediated Signaling
from Orgyia pseudotsugata nuclear polyhedrosis virus (A) Effect of Toso on anti-Fas induced apoptosis. Jurkat.ecoR
cells were infected with pBabeMN-lacZ, pBabeMN-Lyt-2-a9, and(Figure 1C), which might function to initiate some of the
pBabeMN-Toso. Jurkat cells were cultured with 10 ng/ml anti-Fassignaling systems acted on by Toso.
mAb for 24 hr and apoptotic cells counted. The infection frequenciesUsing human 3 Chinese hamster hybrid cell lines and
of pBabeMN-lacZ and pBabeMN-Lyt-2-a9 were 45% and 58%, re-
two human radiation hybrid (RH) mapping panels, the spectively. The percentage of apoptotic cells is expressed as the
toso gene is mapped at 1q31-q32. This region is associ- mean (bars) 6 SD of triplicate cultures. The proportion of apoptotic
ated with several chromosomal abnormalities relating cells in each culture without anti-Fas mAb was less than 2%.
(B) Effect of Toso on anti-Fas-, staurosporine-, and ceramide-to leukemias, as further presented in the Discussion.
induced apoptosis in Jurkat.ecoR cells (triangles) and Jurkat.ecoR
cells infected with pBabeMN-lacZ (squares) and pBabeMN-Toso
(circles). Cells were cultured with these reagents for 24 hr. TheToso Inhibits Fas-, TNFa-, and FADD-Induced
infection frequency of pBabeMN-lacZ was 57%. The percentage of
Apoptosis through Inhibition apoptotic cells are expressed as the mean (symbol) 6 SD (vertical
of Caspase-8 Processing bar) of triplicate cultures.
To characterize the function of Toso, Jurkat.ecoR (Jur- (C) Effect of Toso on anti-Fas mAb±induced apoptosis. Cells were
infected with pBabeMN-Toso-IRES-GFP. After infection, cells werekat cells that express the receptor for ecotropic murine
cultured with (a-Fas (1)) or without (a-Fas (2)) 50 ng/ml of anti-Fasretroviruses) were infected with retroviruses that ex-
mAb. After culture for 5 days, GFP expression in surviving cells waspress Toso and with the control vectors pBabeMN-
analyzed by FACScan.
Toso, pBabeMN-lacZ, and pBabeMN-Lyt-2-a9 (Tagawa
et al., 1986). Jurkat.ecoR cells expressing Toso were
resistant to apoptosis induced by anti-Fas mAb, whereas
were not resistant to any concentration of staurospor-Jurkat cells, Jurkat.ecoR cells, and Jurkat.ecoR cells
ine- or ceramide-induced apoptosis (Figure 2B).that expressed b-galactosidase (lacZ) or Lyt-2-a9 all
It was necessary to verify that the effect of Toso issuccumbed to apoptotic death (Figure 2A).
on the cells expressing Toso and not due to effects uponWe then tested the effect of Toso using other apo-
bystander cells. We performed a mixing experiment inptotic stimuli. Staurosporine, a bacterial alkaloid, is a
which 50% of the cells expressed Toso alone and thebroad-spectrum inhibitor of protein kinases and induces
remaining 50% expressed the lacZ product. After oneprogrammed cell death in various cell lines and dissoci-
round of Fas stimulation, no lacZ-expressing cells re-ated primary cells in culture (Raff et al., 1993). Ceramide
mained, as assayed by X-Gal (data not shown). To de-generation is implicated in a signal transduction path-
termine further that the transduced cells are those thatway that mediates programmed cell death induced by
are protected from apoptosis, we infected Jurkat.ecoRFas and TNFa (Cifone et al., 1994). Although Jurkat.ecoR
cells with pBabeMN-Toso-IRES±green fluorescent pro-cells expressing Toso were resistant to Fas-mediated
apoptosis over a range of anti-Fas dilutions, these cells tein (GFP). In the absence of anti-Fas mAb treatment,
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we observed GFP-negative cells (46%) and GFP-posi-
tive cells (54%) in pBabeMN-Toso-IRES-GFP±infected
Jurkat.ecoR cells. After 5 days of culture with anti-Fas
mAb, we obtained survivors from pBabeMN-Toso-IRES-
GFP±infected Jurkat.ecoR cells, but not from control
pBabeMN-IRES-GFP±infected-Jurkat.ecoR cells (data
not shown); 99.7% of surviving Jurkat cells expressed
GFP, as shown in Figure 2C. These data indicate that
Toso-expressing cells are protected from Fas-induced
apoptosis and suggest that Toso does not exert its effect
as a secreted form.
Since the Fas receptor has homology to the TNFa
receptor, and since these two receptors share analo-
gous signaling systems as well as several intracellular
mediators (Hsu et al., 1996), we investigated the protec-
tive effect of Toso against TNFa-induced apoptosis. Jur-
kat.ecoR cellsexpressing Lyt-2-a9 or Tosowere cultured
with 10 ng/ml of anti-Fas mAb or 1 mg/ml of TNFa in
the presence of 0.1 mg/ml of cyclohexamide for 12 hr.
Toso inhibited Fas-induced apoptosis in the presence
of cyclohexamide and also protected against TNFa-
induced apoptosis in comparison to Jurkat.ecoR ex-
pressing Lyt-2-a9 (Figure 3A). Thus it is likely that the
TNFa and Fas signaling pathways converge at a com-
mon point that can be inhibited by Toso.
Fas-mediated apoptosis is activated through FADD.
We therefore examined the effect of Toso on FADD-
induced apoptosis. Jurkat.ecoR cells expressing Lyt-2-a9
or Toso were infected with pBabeMN-lacZ or pBabeMN- Figure 3. Toso Inhibits Caspase-8 Processing through cFLIP Ex-
pressionFADD. The reinfection efficiency was approximately
(A) Effect of Toso on TNFa-induced apoptosis. Jurkat.ecoR cells40% using pBabeMN-lacZ. As shown in Figure 3B,
expressing Lyt-2-a9 (shaded bars) or Toso (solid bars) were culturedFADD induced apoptosis in 45% of control Jurkat cells.
with 10 ng/ml anti-Fas mAb or 1 mg/ml TNFa in the presence of 0.1However, FADD failed to induce apoptosis in Jur-
mg/ml cyclohexamide for 12 hr, and apoptotic cells were counted.
kat.ecoR cells constitutively expressing Toso. To map The infection frequency of pBabeMN-Lyt-2-a9 was 58%. The per-
the downstream effects of Toso on known inhibitors of centage of apoptotic cells is expressed as the mean (bars) 6 SD of
apoptosis, we investigated whether Bcl-2 and Bcl-XL triplicate cultures.
(B) Effect of Toso on FADD-induced apoptosis. Jurkat.ecoR cellsexpression levels were altered in Toso-expressing cells.
were infected with pBabeMN-Lyt-2-a9 (shaded bars) and pBabeMN-We found that Bcl-2 overexpression can block Fas-
Toso (solid bars). The infection frequency of pBabeMN-Lyt-2-a9 wasinduced apoptosis as well as staurosporine-induced
72%. Jurkat.ecoR cells expressing Lyt-2-a9 or Toso were infected
apoptosis (data not shown). By Western analysis no with pBabeMN-lacZ or pBabeMN-FADD, and apoptotic cells were
change in the levels of expression of Bcl-2 or Bcl-XL counted at 24 hr after infection. The infection frequency of pBa-
was observed (data not shown). Thus it appears that beMN-lacZ in Jurkat.ecoR cells expressing Lyt-2-a9 and Toso was
39% and 43%, respectively. The percentage of apoptotic cells isintracellular signaling events generated by FADD can
expressed as the mean (bars) 6 SD of triplicate cultures.be directly and efficiently blocked by signals emanating
(C) Toso inhibits caspase-8 processing. Jurkat.ecoR cells (control)from Toso at a point prior to engagement of Bcl-2 and
and pBabeMN-Toso-infected Jurkat.ecoR cells (Toso) were culturedBcl-XL. The results also suggest that Toso's effect is not with (1) or without (2) 50 ng/ml of anti-Fas mAb (a-Fas) for 6 hr.
due to down-regulation of FADD gene expression. Caspase-8 processing was analyzed with an enhanced chemilumi-
Our data suggest that Toso inhibits Fas-induced apo- nescence Western blotting analysis system (Amersham Life Sci-
ptosis downstream of FADD, which associates with cas- ence, Arlington Heights, IL) with goat anti-Mch5 p20 antibody (Santa
Cruz Biotechnology, Santa Cruz, CA). The positions of pro-pase-8. Therefore we examined whether caspase-8 pro-
caspase-8 (Pro), the processed form (p20), and the standard markercessing is inhibited by overexpression of Toso. As
are indicated.shown in Figure 3C, the processed form (p20) of FLICE
(D) RT-PCR analysis of cFLIP expression in Jurkat.ecoR cells
after Fas activation was greatly reduced in pBabeMN- (None), pBabeMN-Lyt-2-a9±infected Jurkat.ecoR cells (Lyt-2-a9),
Toso±infected Jurkat.ecoR cells in comparison with and pBabeMN-Toso-infected Jurkat.ecoR cells (Toso). As a control
control Jurkat.ecoR cells. These data indicate that Toso for loading, we amplified b-actin cDNA for 25 cycles.
inhibits caspase-8 processing after Fas activation. Re-
cently, several groups have reported that cFLIP is a
cells that overexpressed Toso, in comparison with con-caspase-8 inhibitor (Hu et al., 1997; Irmler et al., 1997;
trol Jurkat.ecoR cells and Jurkat.ecoR cells that overex-Srinivasula et al., 1997). We performed semiquantitative
pressed Lyt-2. These results suggest that Toso inhibitsreverse transcriptase polymerase chain reaction (RT-
Fas-induced apoptosis by preventing caspase-8 pro-PCR) to detect cFLIP mRNA expression. As shown in
Figure 3D, cFLIP expression was induced in Jurkat.ecoR cessing through cFLIP up-regulation.
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Figure 4. Functional Domain Analysis of
Toso
Effect of Toso deletion mutant expression on
anti-Fas mAb±induced apoptosis. The car-
boxy-terminal amino acid numbers of each
deletion mutant are indicated; the light
shaded bar represents the HA tag. Jurkat.
ecoR cells expressed with mutants were cul-
tured with 10 ng/ml anti-Fas mAb for 24 hr,
and apoptotic cells were counted. The per-
centage of apoptotic cells is expressed as
the mean (bars) 6 SD of triplicate cultures.
ED, extracellular domain; TM, transmem-
brane region.
The Immunoglobulin Domain and the Transmembrane for the anti-apoptotic effects on Fas antibody±stimu-
lated cells. These results indicate that the homologiesRegion of Toso Are Required for Inhibition
of Fas-Induced Apoptosis observed in the cytoplasmic region of Toso, as shown in
Figure 1C, are not the only sources of the anti-apoptoticTo delineate the regions responsible for anti-apoptotic
signal transduction, we assayed epitope-tagged Toso signals generated by a Tosocomplex, although the cyto-
plasmic regions are required for enhancing the anti-(fused to the hemagglutinin [HA] tag) deletion mutants
expressed in our system (Figure 4). The level of expres- apoptotic effects of Toso.
The Toso mutant lacking the transmembrane and cy-sion was similar among most cells expressing the mu-
tants by Western blots (data not shown). Toso.HA had toplasmic domains demonstrated that inhibition of Fas-
induced apoptosis by Toso requires its insertion intoan apparent molecular weight of 60 kDa, suggesting
that Toso is heavily glycosylated (data not shown). To membranes. As shown in Figure 4, TosoD(252±390).HA
afforded no protection from apoptosis. Expression ofexplore whether Toso has an effect on Fas expression,
we analyzed the cell surface expression of Fas using the TosoD(252±390).HA protein was confirmed by West-
ern blot analysis of culture supernatants (data not shown).anti-human Fas mAb, CH11, by fluorescence-activated
cell sorting. Fas was expressed at similar levels on the We further tested whether the effect of supernatants
derived from pBabeMN-TosoD(252±390).HA±transfectedsurface of cells expressing either full-length Toso, Toso
deletion mutants, or control vector (data not shown). 293T cells could block Fas-induced apoptosis in Jurkat
cells. The TosoD(252±390).HA±containing supernatantsThus, Toso neither down-regulates Fas nor directly in-
terferes with the ability of the antibody to bind and pre- did not inhibit Fas-induced apoptosis, indicating that a
membrane-proximal event dependent on cis localizationsumably stimulate Fas.
Next we attempted to induce apoptosis in cells ex- of Toso is required for blockade of the Fas-mediated
death signal.pressing Toso or these mutants using 10 ng/ml anti-Fas
mAb. Apoptosis was readily induced in control Jurkat. We tested whether the immunoglobulin domain of
Toso could influence the anti-apoptotic behavior of thisecoR cells and Jurkat.ecoR cells expressing Lyt-2-
a9.HA, whereas apoptosis was markedly inhibited in molecule. As can be seen in Figure 4, disruption of the
immunoglobulin domain completely abrogated the anti-Jurkat.ecoR cells expressing Toso.HA (Figure 4). Dele-
tions of regions of the cytoplasmic domain of Toso from apoptotic ability of Toso (TosoD(29±187).HA). Further-
more, a chimeric Lyt-2-Toso fusion protein in which the334 to 390 still inhibited apoptosis. Moreover, a Toso
deletion mutant lacking the entire cytoplasmic domain cytoplasmic domain of Toso was coupled to the extra-
cellular and transmembrane region of Lyt-2-a9 failed tostill retained substantial anti-apoptotic ability. Thus the
cytoplasmic domain of Toso is not absolutely required inhibit Fas-induced apoptosis. We also used anti-mouse
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CD8a mAb (Lyt-2) to cross-link the Lyt-2-Toso chimeras
to determine whether induced multimerization of the
Toso cytoplasmic domains enhanced their anti-apo-
ptotic abilities. Jurkat.ecoR cells that express thechime-
ric Lyt-2-Toso fusion protein did not showany protection
against anti-Fas mAb±induced apoptosis in the pres-
ence of anti-mouse CD8a mAb (data not shown).
These results suggest that some form of immunoglob-
ulin domain±mediated dimerization of Toso is required
to initiate the anti-apoptotic effect in conjunction with
the cytoplasmic region of Toso or other cell surface
Toso-associating proteins. To test this hypothesis, we
cross-linked cell surface molecules on Toso.HA-express-
ing Jurkat.ecoR cells using the water-soluble cross-
linker BS3 (Pierce, Rockford, IL). We detected apparent
cross-linking molecular complexes at 150, 240, and 300
kDa (data not shown). This result first indicates that
Toso is a surface-expressed receptor. The results are
consistent with an association of Toso with another sur-
face protein(s) of molecular weight 90 kDa. The several
molecular weights observed for the cross-linked com-
plexes are also minimally consistent with stochiometric
mixtures of 60 and 90 kDa molecules.
T Cell Signaling Leading to Apoptosis
Is Blocked by Activated Toso
We surveyed toso mRNA expression in several human
tissues (Human RNA Master Blot, Clontech Labora-
tories) using the toso-coding region probe (1.2 kbp).
Toso expression was observed in lymph nodes, lung,
and kidney. In addition, we detected faint signals from
spleen, thymus, liver, heart, and salivary gland (Figure
Figure 5. Expression of Toso in Several Human Tissues and Human5A). To analyze Toso expression in immune tissues, we
Cell Linesperformed Northern blot analysis (human immune sys-
(A) mRNA dot blot analysis of the tosogene inseveral human tissues.tem multiple-tissue Northern Blot II, Clontech). Asshown
A1, whole brain; A2, amygdala; A3, caudatenucleus; A4, cerebellum;
in Figure 5B, we detected endogenous toso mRNA spe- A5, cerebral cortex; A6, frontal lobe; A7, hippocampus; A8, medulla
cies of 2.0 (major), 2.8, 3.5, and 4.3 kbp in lymph node oblongata; B1, occipital lobe; B2, putamen; B3, substantia nigra;
and spleen. The nucleotide length of the cDNA was 1.9 B4, temporal lobe; B5, thalamus; B6,subthalamic nucleus; B7, spinal
cord; C1, heart; C2, aorta; C3, skeltal muscle; C4, colon; C5, bladder;kbp, suggesting that the additional bands might either
C6, uterus; C7, prostate; C8, stomach; D1, testis; D2, ovary; D3,be alternative splice products or incompletely processed
pancreas; D4, pituitary gland; D5, adrenal gland; D6, thyroid gland;messages. Toso expression was also observed in pe-
D7, salivary gland; D8, mammary gland; E1, kidney; E2, liver; E3,
ripheral blood leukocytes (PBLs) and thymus (Figure small intestine; E4, spleen; E5, thymus; E6, PBL; E7, lymph node;
5B). Expression in bone marrow and fetal liver was much E8, bone marrow; F1, appendix; F2, lung; F3, trachea; F4, placenta;
lower than that in lymph node and spleen, as seen after G1, fetal brain; G2, fetal heart; G3, fetal kidney; G4, fetal liver; G5,
fetal spleen; G6, fetal thymus; G7, fetal lung.overexposure of the blot (data not shown).
(B) Northern blot analysis of the toso gene in several human immuneTo analyze which cell types express Toso, we assayed
tissues. Positions and sizes (kilobase pairs) of toso mRNA are indi-expression of Toso in several human cell lines by semi-
cated. The film was exposed at 2708C with an intensifying screenquantitative RT-PCR involving amplification of the 1.2 for 1 day.
kbp coding region of toso (Figure 5C). We detected toso (C) RT-PCR analysis of Toso in human cell lines (top). Positions and
mRNA in lymphoid cell lines such as Jurkat cells (T cell sizes (kilobase pairs) of Toso and standard nucleotide makers are
indicated. As a control for loading, we amplified b-actin cDNA (bot-leukemia), CemT4 cells (T cell leukemia), MolT-4 cells
tom); the number of cycles is indicated at right.(T cell leukemia), HB11.19 cells (B cell lymphoma), and
Reh cells (acute lymphocytic leukemia; non-T, non-B).
HL-60 cells (promyelocytic leukemia) displayed a con- leukemia), Ocl-Ly8 and AMK cells (both human B cell
lines, transformed with Epstein-Barr virus), Reh cells,sistently weak signal. In contrast, toso PCR products
were not detected in nonhematopoietic cell lines, includ- HL-60 cells, and HepG2 cells using pBabeMN-Toso-
IRES-neo to allow cotranslational selection with Genet-ing HepG2 cells (hepatoblastoma), 293 cells (kidney,
transformed with adenovirus), and Hela cells (cervix, icin (Gibco BRL). All of the human T cell lines and one
of the human B cell lines, Ocl-Ly8 cells, in which Tosoadenocarcinoma). Toso therefore is expressed in cells
of hematopoietic cells. was overexpressed, were inhibited for apoptosis in-
duced by anti-Fas mAb, whereas no significant protec-We expressed Toso in several human cell lines, includ-
ing Jurkat cells, CemT4 cells, SupT1 cells (human T cell tion was observed against Fas-induced apoptosis in the
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othercell lines (data not shown).Thus, theanti-apoptotic
effect of Toso also is limited to certain classes of hema-
topoietic cells, suggesting the presence of tissue-spe-
cific mediators in these cells.
T cell activation results in increased expression of Fas
and FasL on the cell surface. This is paradoxical, since
it is clear that T cells do not kill themselves after such
induction, whereas overexpression of Fas and FasL in
other cell types does lead to cell death. In vitro, phorbol
myristate acetate (PMA) and ionomycin can induce apo-
ptosis in T cells (Oyaizu et al., 1995) by mimicking certain
aspects of CD3 engagement, including up-regulation of
Fas and FasL. We hypothesized that one function of
Toso might be to inhibit T cell±activated self-killing and
that the levels of Toso might increase following T cell
activation, helping to render Jurkat cells partially resis-
tant to up-regulated Fas and FasL. Expression of toso
mRNA in Jurkat cells was therefore examined by North-
ern hybridization. As shown in Figure 6A, we detected
an endogenous toso mRNA species of 2.8 kbp in resting
Jurkat cells, although expression was seen best after
overexposure of the blot (data not shown). Interestingly,
we found increases in toso mRNA expression, including
minor species (2.0, 3.5, 4.3, and 5.5 kbp), after stimula-
tion of Jurkat cells with PMA and phytohemagglutinin
(PHA) (15-fold increase) or PMA in combination with
ionomycin (25-fold increase). Thus, Toso expression can
be induced following T cell activation.
We hypothesized that induced endogenous Toso ex-
pression would correlate with induced resistance to
Fas-mediated apoptosis. As shown in Figure 6B, Jurkat
Figure 6. Inducible Expression of Toso and Resistanceto Apoptosis
cellswere susceptible to anti-Fas mAb±induced apopto- after Stimulations with T Cell Activator
sis as well as PMA/ionomycin-induced apoptosis. How- (A) Northern blot analysis of the toso gene in Jurkat cells (None)
ever, following activation with PMA/ionomycin, one third and Jurkat cells stimulated with PMA and PHA (PMA 1 PHA) or
of Jurkat cells were clearly resistant to anti-Fas mAb± PMA and ionomycin (PMA 1 Io.). The positions and sizes (kilobase
induced apoptosis. These results suggest that Jurkat pairs) of toso mRNA are indicated.
(B) Activation-induced resistance to anti-Fas mAb±induced apopto-cells activate a protective system that blocks Fas-medi-
sis in Jurkat cells. Jurkat cells were precultured with 10 ng/ml PMAated apoptosis, supporting the contention that induced
and 500 ng/ml ionomycin for 12 hr and then incubated with 10 ng/protein, such as Toso, is a mediator in this protective
ml of anti-Fas mAb for 24 hr. The percentage of apoptotic cells iseffect.
expressed as the mean (bars) 6 SD of triplicate cultures.
We therefore tested whether Toso expression could (C) The effect of Toso on PMA and ionomycin (PMA 1 Io.)±induced
rescue activation-induced programmed cell death. We apoptosis. The infection frequency of pBabeMN-lacZ was 42%. Jur-
randomly picked five pBabeMN-Toso±infected Fas-resis- kat.ecoR cells (2), Jurkat.ecoR cells infected with pBabeMN-lacZ
(lacZ), and pBabeMN-Toso-infected clones (Toso clones 1±5) weretant Jurkat T cell clones and used them to assay the
cultured with 10 ng/ml of anti-Fas mAb (left) and 10 ng/ml PMA andinhibitory effect of Toso on PMA/ionomycin-induced
500 ng/ml ionomycin (right) for 24 hr. The percentage of apoptoticapoptosis. All five clones exhibited significant resis-
cells is expressed as the mean (bars) 6 SD of triplicate cultures.tance to PMA/ionomycin-induced apoptosis, as well as (D) RT-PCR analysis of Toso (the 1.2 kbp fragment of Toso) in periph-
continued strong resistance to Fas-induced apoptosis eral blood mononuclear cells after activation with PHA (top left) and
(Figure 6C). Control clones displayed the expected kill- in peripheral blood mononuclear cells after allogenic stimulation
ing effect when activated with PMA and ionomycin. Toso (top right). For allogenic stimulation, stimulator cells (SC), responder
cells (RC), or mixed cells (RC 1 SC) were cultured for 1 day (day 1)not only inhibited apoptosis activated by Fas and TNFa,
and 6 days (day 6). As a control for loading, we amplified b-actinbut also inhibited apoptosis induced by certain classes
cDNA (bottom).of T cell activation events.
Normal T cells at early stages of activation are resis-
performed to determine whether Toso is activated intant to Fas-induced apoptosis but become Fas sensitive
primary immune cells upon T cell activation. As shownat late stages of activation (Klas et al., 1993). We there-
in Figure 6D, Toso expression was also rapidly inducedfore examined Toso expression kinetics after PHA stim-
in the presence of stimulator cells on day 1; however,ulation in peripheral blood mononuclear cells using
Toso expression in mixed lymphocyte cultures was re-semiquantitative RT-PCR. We observed Toso expres-
duced by day 6. The level of expression on day 6 wassion at day 1 and up-regulated expression at day 3
lower than the level of expression on day 1 and in re-after activation. However, Toso expression was clearly
sponder cells alone on day 6. These results further con-decreased at days 5 and 7 (Figure 6D), correlating with
firm a supportive role for Toso-induced resistance toFas sensitivity studies (Klas et al., 1993). Furthermore,
allogenic stimulation in mixed lymphocyte cultures was Fas-mediated death during T lymphocyte activation.
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finding, Toso also did not inhibit ceramide-induced apo-
ptosis, which acts downstream of or independently of
caspase-3, as demonstrated in experiments using the
caspase-3±specific inhibitor tetrapeptide aldehyde DEVD-
CHO (Gamen et al., 1996), which does not inhibit cera-
mide-induced apoptosis. Overexpression of Bcl-2 or
Bcl-XL is known to prevent apoptosis in response to
ceramide and staurosporine (Takayama et al., 1995;
Zhang et al., 1996; Geley et al., 1997; Susin et al., 1997).
Toso did not change the expression levels of Bcl-2 or
Bcl-XL in Jurkat cells, showing that neither Bcl-2 nor
Bcl-XL was involved in the protective activities of Toso.
Thus, Toso activates an inhibitory pathway that prevents
caspase-8 activation following Fas stimulation, rather
than blocking apoptotic signals downstream or at the
level of caspase-3. This explains the apparent specificity
of the blockade to TNF family±related surface receptors
that use caspase-8 for apoptotic signaling.
Figure 7. A Model of the Role of Toso in T Cell Activation There is some diasagreement over the role of cFLIP
In thismodel, Toso is induced followingT cellactivation andprotects in apoptosis. cFLIP in some studies was observed to
T cells from self-induced programmed cell death. The inhibitory induce apoptosis in certain situations, although cFLIP
effects of Toso on Fas signaling maps at the level of caspase-8 itself lacks any caspase activity (Goltsev et al., 1997;
through induced expression of cFLIP.
Irmler et al., 1997; Shu et al., 1997). Irmler et al. (1997)
suggested that the death resulting in some cells from
Discussion expression of protein is artificial and that the protein's
sole function is to inhibit cell-death induction as domi-
Using a functional screen for genes that regulate Fas- nant-negative form of caspase-8. In contrast, Shu et al.
mediated apoptosis, we cloned and characterized a (1997) proposed that cFLIP acts as a death activator,
novel immunoglobulin domain±containing polypeptide, prompting activation of caspase-10 upon binding to
Toso, with potent pathway-specific anti-apoptotic effects caspase-3 and also enhancing death by displacement
in hematopoietic cells. Toso exerted an inhibitory activ- of the putative death-inhibiting c-IAPs (cellular inhibitors
ity against apoptosis induced by Fas-, TNFa-, FADD-, of apoptosis protein) from TRAF-2. cFLIP might have
and PMA/ionomycin but not against staurosporine- or multiple functions depending on the cell type and stimu-
ceramide-induced apoptosis. Mechanistically, the block lus involved. Its involvment and up-regulation in Toso
to apoptotic activation, and the pathway specificity of signaling might reflect a more complex role for Toso in
the effect, are most likely explained by inhibition of cas- the immune system that is yet to be examined.
pase-8 processing through induction of cFLIP expres- This is consistent with the proposal that Toso expres-
sion (a model summarized in Figure 7). Because Toso sion, which transiently increased and then decreased
is expressed within lymphoid tissues and hematopoietic in peripheral blood mononuclear cells after activation
cells and is enhanced after T cell activation, which also with PHA or allogenic stimulation, is responsible for the
transmits activation signals leading to up-regulation of temporary Fas resistance in T cells. Hence, the results
Fas and FasL, this model suggests an important role are consistent with the hypothesis that Toso may be
for this molecule in immune system processes. As a involved in activation-induced resistance to apoptosis
reflection of its important protective effects, we named of T cells during an immune response. We conclude
the molecule Toso after a Japanese liquor that is drunk from the results that the inhibitory effect of Toso in
on New Year's Day to celebrate long life and eternal activation-induced apoptosis is attributable to the inhi-
youth. bition of Fas-mediated signal transduction through inhi-
bition of caspase-8, possibly mediated through cFLIP.
A Specific Inhibitor of Apoptosis
in Hematopoietic Cells
Death signals through Fas and through the TNF type I Domain Analysis of Toso Suggests Multiple
Interacting Partnersreceptor are mediated by adapter molecules such as
FADD/MORT1 as well as by receptor-associated cas- Deletion analysis of Toso indicated that surface expres-
sion of the IgV-like region is necessary to inhibit Fas-pases such as caspase-8. Toso inhibited Fas-, TNFa-
and FADD-induced apoptosis. Furthermore, Toso up- induced apoptosis and that the cytoplasmic domain of
Toso is insufficient and indeed partly expendable forregulated cFLIP expression and inhibited caspase-8
processing, mapping a primary Toso anti-apoptotic ef- the anti-apoptotic function. Deletion of the cytoplasmic
domain resulted in abrogation of only about half of thefect at the level of inhibition of caspase-8 activity. Toso
did not inhibit staurosporine-induced programmed cell anti-apoptotic effect. This suggests that Toso must be
expressed at the cell surface in a manner such that itdeath, and staurosporine has been shown to activate
caspase-3 (Jacobsen et al., 1996). Therefore, additional presumably interacts other surface molecule(s) that
propagate an anti-apoptotic signal. We suspect thatToso anti±apoptotic effects do not occur either down-
stream of or at the level of caspase-3. Supporting this Toso forms a heterodimer with this other surface protein
Toso, a Regulator of Fas-Induced Apoptosis
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RNA Detection Using PCRto collaborate in initiating the anti-apoptotic signal. In-
RT-PCR was performed for 35 cycles using primers 59-AGG GGCteractions of surface-expressed Toso complexes with
TCT TGG ATG GAC (TosoS) and 59-CTG GGG TTG GGG ATA GCligands on or near target cells might also modulate the
(TosoA). Hybridization was carried out with the 32P-labeled BamHI±
ability of Toso to provide anti-apoptotic signaling. We XhoI fragment (510 bp). To detect cFLIP mRNA expression, we
are currently investigating the existence of such ligands amplified a 1.1 kbp fragment (998±2061) of the cFLIP gene with
and contributory molecules. primers 59-GGG AGA AGT AAA GAA CAA AG and 59-CGT AGG CAC
AAT CAC AGC AT for 35 cycles.Since Toso is a negative regulator of Fas-mediated
cell death in lymphoid cells, it therefore could be in-
Chromosomal Mappingvolved in oncogenic events or resistance to chemother-
Genomic DNAs from a panel of 17 human 3 Chinese hamster hybridapy (Friesen et al., 1996). The toso gene localizes within
cell lines (Francke et al., 1986) were analyzed by PCR using Toso-
human chromosome region 1q31-q32. Chromosomal specific primers, 59-AGA GGC ATA GCT ATT GTC TCG G (sense,
changes in 1q32 are frequently observed in human can- located 369 bp downstream of the coding region) and 59-ACA TTT
cers, including various types of hematopoietic malig- GGA TCA GGG CAA AG (antisense, 508 bp downstream of the
nancies and solid tumors (Schmid and Kohler, 1984; coding region). Specific PCR products were obtained from human
genomic DNA and hybrid cell lines that carry human chromosomeWaghray et al., 1986; Jinnai et al., 1990; Yip et al., 1991;
1 (data not shown). To map the toso gene locus more precisely,Shah et al., 1992; Mertens et al., 1997; Mitelman et al.,
two human RH mapping panels were typed by PCR (Cox et al.,1997). Furthermore, studies in nude mice demonstrated
1990; Walter et al., 1994). In the Stanford G3 mapping panel G3
that duplication of the chromosome segment of 1q11- (Stanford Human Genome Center), Toso cosegregated with chromo-
q32 is associated with proliferation and metastasis of some 1 marker D1S3553, a known marker of chromosome 1 bin 115
human chronic lymphocytic leukemic B cells (Ghose et on the SHGC RH map, on all 83 Stanford G3 panel RH cell lines. In
al., 1990), suggesting the presence of dominantly acting the GeneBridge 4 mapping panel (Whitehead Institute/MIT Genome
Center), Toso is located 5.4 centirays3000 and 1.7 centirays3000 fromgrowth-regulatory or cell survival genes. Thus, Toso is a
D1S504 and WI-9641, respectively. The order of loci in this regioncandidate for evaluation as a proto-oncogene in several
from centromere to qter is: D1S412, D1S306, D1S504, Toso, WI-proliferative and metastatic neoplasms.
9641, D1S491, D1S237. According to Bray-Ward et al. (1996), the
The finding that Toso can exert cell-specific and sig- yeast artificial chromosomes (YACs) containing the more proximal
naling pathway±specific effects on apoptosis suggests markers D1S412 (bin 104), D1S477 (bin 109), and D1S504 (bin 114)
that other polypeptides exist that act on the Fas death were mapped to 1q25-q32, 1q31-q32, and 1q25-q32 respectively,
induction cascade. Critically, the demonstration that and the YACs containing the more distal markers D1S491 (bin 118),
D1S414 (bin 121) and D1S237 (bin 124) were mapped to essentiallyToso signaling induces expression of cFLIP suggests
the same region: 1q31-q32, 1q31-q32, and 1q32-q41, respectively.the existence of a regulatable transcription cascade that
can be activated to block Fas-mediated apoptosis in
Quantification of Apoptosissome cell types. Further analysis of the Toso pathway
We stained cells with 100 mg/ml ethidium bromide and 100 mg/
coupled with gene disruption analysis in mice will pro- ml acridine orange (both Sigma) in phosphate-buffered saline after
vide clues about the overall role that Toso plays in inhib- incubation with several reagents such as anti-Fas mAb (Kamiya
iting activation-induced T cell apoptosis in vivo. Biomedical Company), staurosporine (Sigma), ceramide (Sigma),
PMA (Sigma)/ionomycin (Sigma), and human TNFa (R&D Systems)/
cycloheximide (Sigma). Apoptotic cells were identified with ultravio-Experimental Procedures
let microscopy as described (MacGahon et al., 1995). For FADD-
induced apoptosis, mouse FADD (a gift from Dr. Angeles Estelles,Screening of cDNA Library
Stanford University) was ligated into pBabeMN retroviral vector.A retroviral library containing 2 3 106 independent cDNA inserts
was constructed from Jurkat cell mRNA by standard methods (Kita-
mura et al., 1995; Kinoshita and Nolan, unpublished data), using a Preparation and Culture of Peripheral Blood
retrovirus vector pBabeMN (Kinoshita et al., 1997). We transfected Mononuclear Cells
the library into an amphotropic virus packaging cell line, φNX- PBLs from healthy volunteers were used. Adherent cells were re-
Ampho, which produces infectious retrovirus at up to 5 3 106 infec- moved by adherence to plastic culture vessels. Cells were activated
tious units/ml, as described previously. We spin-infected Jurkat with PHA-P (1 mg/ml) for 24 hr, washed, and cultured with 20 U/ml
cells with the supernatant from φNX-Ampho cells at 2500 rpm for of recombinant human IL-2 (R&D Systems). To perform mixed lym-
1.5 hr at 328C. Cells were then placed at 328C for 12 hr and then phocyte culture, PBLs were treated with 20 mg/ml of mitomycin-C
incubated at 378C for 48 hr to allow integration and expression of (stimulating cells) for 3 hr and washed. Stimulating cells were ad-
the retrovirus. We achieved 20%±40% infection as determined by justed to 7 3 105 cells/ml and cultured with an equal volume and
doping of the library with marker retroviruses pBabeMN-lacZ and cell density of PBLs (responding cells) from another donor (Clot et
pBabeMN-Lyt-2-a9. al., 1975).
Jurkat cells were aliquoted into 96-well plates (2 3 104/well) in
100 ml of RPMI 1640 media including 10 ng/ml of anti-human Fas
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